8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 26, 2023

9 Meters Biopharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37797	27-3948465
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

4509 Creedmoor Road, Suite 600, Raleigh, NC 27612

(Address of principal executive offices) (Zip Code)

(919) 275-1933

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock $0.0001 Par Value	NMTR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

John Temperato, the Chief Executive Officer (the “CEO”) and a Class II director on the Board of Directors (the “Board”) of 9 Meters Biopharma, Inc. (the “Company”) resigned from his role as CEO and director of the Company, effective at the close of business on May 26, 2023. The Board appointed Bethany Sensenig, Chief Financial Officer of the Company, to serve as Interim Chief Executive Officer, and principal executive officer for SEC purposes, of the Company, in addition to her current responsibilities. Mr. Temperato’s departure is not related to any matter relating to the Company’s operations, policies or practice.

Ms. Sensenig joined the Company as Chief Financial Officer in January 2022. Prior to joining the Company from March 2019 to January 2022, Ms. Sensenig was Chief Financial Officer and Head of U.S. Operations of Minovia Therapeutics, Ltd., a clinical-stage biotech company, where she held a leadership role building the company’s business and financing strategy. From April 2006 to March 2019, Ms. Sensenig held various roles at Biogen, Inc. a multinational biotechnology company, where she most recently held the position of Vice President of Finance and Commercial Operations. Earlier in her career, Ms. Sensenig held financial management and analyst roles at Merck & Co. Inc. and Nexus Technologies, Inc. Ms. Sensenig holds a Bachelor of Science in Accounting and Business Management from Montreat College, a Master of Business Administration from Western Carolina University and is a Certified Management Accountant.

Ms. Sensenig is 47 years old and has no familial relationships with any executive officer or director of the Company. There have been no transactions in which the Company has participated and in which Ms. Sensenig had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.

In connection with Mr. Temperato’s resignation from employment, the Company has entered into a Separation Agreement and Release with Mr. Temperato, dated May 29, 2023 (the “Separation Agreement”). Pursuant to the Separation Agreement, Mr. Temperato will be entitled to severance benefits including payment of his annual base salary for twelve months (the “Severance Period”), as well as a pro-rated bonus for 2023 at target, and 12 months’ additional vesting of his outstanding equity awards. The foregoing will be subject to continued compliance with existing restrictive covenants under his employment agreement with the Company and execution and non-revocation of a release of claims.

The foregoing summary of the terms of the Separation Agreement is qualified in its entirety by reference to the complete text of the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
Exhibit 10.1	Separation Agreement and Release between John Temperato and 9 Meters Biopharma, Inc., dated May 29, 2023.
Exhibit 99.1	Press Release dated May 30, 2023.
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	9 Meters Biopharma, Inc.
Date: May 30, 2023	By:	/s/ Bethany Sensenig
		Bethany Sensenig
		Chief Financial Officer

EX-10.1

SEPARATION AGREEMENT AND RELEASE

This SEPARATION AGREEMENT AND RELEASE (the “Agreement”) is hereby made and entered into this 26th day of May, 2023 by and between 9 Meters Biopharma, Inc. (f/k/a Innovate Biopharmaceuticals, Inc.), a Delaware corporation (the “Company”), and John Temperato (the “Executive”). The Company and the Executive are referred to herein individually as a “Party” and collectively as the “Parties.”

    WHEREAS, the Parties executed an Executive Employment Agreement on April 30, 2020 (the “Original Agreement”); and,

    WHEREAS, the Parties amended the Original Agreement pursuant to the First Amendment to Employment Agreement executed by the Parties on July 21, 2021 (the “Amendment”) (the Original Agreement and the Amendment collectively referred to herein as the “Employment Agreement”); and,

    WHEREAS, Executive has informed the Company of his voluntary resignation pursuant to Section 5(a)(i) of the Employment Agreement; and,

    WHEREAS, pursuant to Section 13 of the Employment Agreement, the Company and Executive have agreed to waive the 30-day notice period of Section 5(a)(i), making Executive’s resignation effective May 26, 2023; and,

    WHEREAS, the Company has offered, and Executive has accepted, the terms of this Agreement providing certain severance benefits to Executive.

NOW THEREFORE, in consideration of the benefits provided to Executive herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows.

    1.    Resignation; Resignation from Board of Directors. Except as set out in this Agreement, as provided by the specific terms of a benefit plan or as required by law, upon the resignation of Executive’s employment with the Company and Insperity PEO Services, L.P. (“Insperity”), effective as of May 26, 2023 (the “Resignation Date”), all of Executive’s employee benefits with the Company and Insperity will terminate. Executive hereby represents that he has returned to the Company all Company-owned equipment, keys or passes, software, files, samples, training materials, programs and documents (including any copies) in the same condition as when provided to Executive, reasonable wear and tear excepted. Executive’s return of Company property is an express requirement under this Agreement and a condition to Executive’s receipt of the Separation Benefits described in Section 2 below. Executive’s final paycheck will include payment for his accrued but unused vacation time, in a lump sum amount of $42,553, less applicable withholdings and deductions. Upon receipt of Executive’s final paycheck from the Company and/or Insperity, Executive agrees and acknowledges that he will have been paid all wages for labor or services rendered by Executive for the Company and Insperity or on the Company or Insperity’s behalf as an employee through the Resignation Date. Executive agrees that, effective as of the Resignation Date, Executive has resigned from all positions as an officer of the Company and its affiliates and as a member of the Company’s Board of Directors (and the board of directors of any of its affiliates, as applicable). In furtherance of the preceding sentence, Executive will execute and return to the Company all letters and documents that the Company may reasonably require in order to evidence such resignation(s).

    2.    Separation Benefits. Provided that Executive timely signs and returns this Agreement to the Company and does not revoke this Agreement as provided in Section 9 below, the Company will pay Executive the following (the “Separation Benefits”):

a)Separation Pay. The Company will continue to pay Executive’s then-current Base Salary (as that term is defined in the Employment Agreement) as of the Resignation Date, less applicable withholdings and deductions, for a period of twelve (12) months following the Resignation Date (the “Severance Period”) in accordance with the Company’s normal payroll practices for its employees. The Company will make its first payment of this obligation on the first regularly scheduled pay date of the Company processed after Executive has executed, delivered to the Company and not revoked this Agreement). The Company’s first payment will include a catchup

for any amounts that would have otherwise been paid to Executive had this Agreement been effective as of the Resignation Date.

b)Prorated Bonus. The Company will pay Executive a prorated amount of Executive’s target bonus for 2023, if any, in accordance with and subject to Section 4(b) of the Employment Agreement. Such payment shall be made at the time the Company pays other employee bonuses for 2023, but in no event later than March 31, 2024.

c)Accelerated Vesting. The Company will accelerate the vesting of Executive’s unvested Options and RSUs (as each of those terms are defined in the Employment Agreement), if any, that were scheduled to vest in the twelve (12) month period immediately following the Resignation Date.

If Executive does not sign this Agreement and return it to the Company within twenty-one (21) days of his receipt of it, or if Executive revokes it pursuant to Section 9 below, Executive will not be entitled to receive the Separation Benefits described above.

    As a condition of receiving the Separation Benefits, Executive agrees to sign any documentation required of him by Insperity, including, but not limited to, an additional release.

3.    Release of Claims. In exchange for the Company providing Executive with the Separation Benefits described in Section 2 above, by signing this Agreement, Executive releases and forever discharges the Company and Insperity, as well as their respective officers, directors, shareholders, members, partners, employees, agents, representatives, attorneys, lessors, lessees, licensors and licensees, owners, and their respective successors, assigns, heirs, executors and administrators (collectively, the “Company Parties”), from any and all claims, demands, and causes of action of every kind and nature, whether known or unknown, direct or indirect, accrued, contingent or potential, which Executive ever had or now has, including but not limited to any claims arising out of or related to Executive’s employment with the Company and the termination thereof (except where and to the extent that such a release is expressly prohibited or made void by law). This release includes, without limitation, Executive’s release of the Company and the Company Parties from any claims by Executive for lost wages or benefits, compensatory damages, punitive damages, attorneys’ fees and costs, equitable relief or any other form of damages or relief. In addition, this release is meant to release the Company and the Company Parties from all common law claims, including claims in contract or tort, including, without limitation, claims for breach of contract, wrongful or constructive discharge, intentional or negligent infliction of emotional distress, misrepresentation, tortious interference with contract or prospective economic advantage, invasion of privacy, defamation, negligence or breach of any covenant of good faith and fair dealing. Executive also specifically and forever releases the Company and the Company Parties (except where and to the extent that such a release is expressly prohibited or made void by law) from any and all claims under North Carolina laws prohibiting discrimination, harassment and retaliation, and all similar state and local laws, and all claims under federal law based on unlawful employment discrimination, harassment or retaliation, including, but not limited to, claims for violation of Title VII of the Civil Rights Act, the Americans with Disabilities Act, the Genetic Information and Discrimination Act, and the Federal Age Discrimination In Employment Act (29 U.S.C. § 621 et. seq.).

Executive acknowledges that this release applies both to known and unknown claims that may exist between Executive and the Company (or between Executive and any of the Company Parties). Executive expressly waives and relinquishes all rights and benefits which Executive otherwise may have under any state or federal statute or common law principle that would otherwise limit the effect of this Agreement to claims known or suspected prior to the date Executive executes this Agreement, and do so understanding and acknowledging the significance and consequences of such specific waiver. In addition, Executive hereby expressly understands and acknowledges that it is possible that unknown losses or claims exist or that present losses may have been underestimated in amount or severity, and Executive explicitly took that possibility into account in agreeing to this release.

    Notwithstanding the foregoing, nothing in this Agreement prohibits Executive from filing a charge with, or participating in any investigation or proceeding conducted by, the U.S. Equal Employment Opportunity Company or a comparable state or federal fair employment practices agency; provided, however, that this Agreement fully and finally resolves all monetary matters between Executive and the Company and the Company Parties, and by signing this Agreement, Executive is waiving any right to monetary damages, attorneys’ fees and/or costs related to or arising from any such charge,

1

complaint or lawsuit filed by Executive or on Executive’s behalf, individually or collectively. In addition, nothing in this Agreement extinguishes any claims Executive may have against the Company for breach of this Agreement or any claims arising from events that occur following the effective date of this Agreement.

    4.    No Admissions. Executive understands, acknowledges and agrees that the release set out above in Section 3 is a final compromise of any potential claims by Executive against the Company and/or the Company Parties in connection with Executive’s employment by the Company, and is not an admission by the Company or the Company Parties that any such claims exist or that the Company or any of the Company Parties are liable for any such claims. By signing this Agreement, Executive agrees and acknowledges that he has no cause to believe that any violation of any local, state or federal law has occurred with respect to Executive’s employment or separation of employment from the Company.

    5.    Confidentiality. Executive hereby represents and agrees that he will not (except as required by law) disclose information regarding the specific terms of this Agreement, to anyone except Executive’s immediate family, his attorney, his accountant or his financial advisor as reasonably necessary. Should the disclosure of any confidential or proprietary information of the Company be required of Executive (a) in response to any summons or subpoena, (b) in connection with any litigation, or (c) in order to comply with any law, order, regulation, request of any government or regulatory agency or ruling, prior to making any disclosure, Executive agrees to inform the Company of any such request or compelled disclosure as soon as possible, and, to the extent possible, afford the Company the opportunity to contest such disclosure. Provided, however, nothing in this Agreement prohibits Executive from reporting possible violations of federal law or regulation to any governmental agency or entity, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation, and Executive does not need to give notice to or obtain the prior authorization of the Company to make such reports or disclosures.

Pursuant to the Defend Trade Secrets Act of 2016, Executive is notified that an individual will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to his attorney and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.

    6.    No Disparagement. Executive agrees that, following the Resignation Date, Executive will not falsely denigrate, defame, disparage or cast aspersions upon the Company, the Company Parties, their products, services, business and manner of doing business, and that Executive will use his reasonable best efforts to prevent any member of Executive’s immediate family from engaging in any such activity; provided, however, nothing in this Agreement prohibits Executive from providing truthful information and/or testimony in connection with any investigation or proceeding conducted by, the U.S. Equal Employment Opportunity Company, a comparable state or federal fair employment practices agency, the Securities and Exchange Commission, or any other government agency.

    7.    Relief and Enforcement. Executive understands and agrees that any breach of this Agreement by Executive will relieve the Company of its obligation to provide any unpaid Separation Benefits described in Sections 2, above and to recover any amounts paid to Executive. Executive also understands and agrees that if he violates the terms of Sections 5 or 6 of this Agreement, Executive will cause injury to the Company (and/or one or more of the Company Parties) that will be difficult to quantify or repair, so that the Company (and/or the Company Parties) will have no adequate remedy at law. Accordingly, Executive agrees that if he violates Sections 5 or 6 of this Agreement, the Company (or the Company Parties) will be entitled as a matter of right to obtain an injunction from a court of law, restraining Executive from any further violation of this Agreement. The right to an injunction is in addition to, and not in lieu of, any other remedies that the Company (or the Company Parties) has at law or in equity.

    8.    No Modifications; Governing Law; Entire Agreement. This Agreement cannot be changed or terminated verbally, and no modification or waiver of any of the provisions of this Agreement

2

will be effective unless it is in writing and signed by both Parties. The Parties agree that this Agreement is to be governed by and construed in accordance with the laws of the State of North Carolina, and that any suit, action or charge arising out of or relating to this Agreement will be adjudicated in the state or federal courts in Wake County, North Carolina. This Agreement sets forth the entire and fully integrated understanding between the Parties, and there are no representations, warranties, covenants or understandings, oral or otherwise, that are not expressly set out herein.

    9.    Right to Revoke. ONCE SIGNED BY EXECUTIVE, THIS AGREEMENT IS REVOCABLE IN WRITING FOR A PERIOD OF SEVEN (7) DAYS (THE “REVOCATION PERIOD”). IN ORDER TO REVOKE HIS ACCEPTANCE OF THIS AGREEMENT, EXECUTIVE MUST DELIVER WRITTEN NOTICE TO MARK SIRGO, AND SUCH WRITTEN NOTICE MUST ACTUALLY BE RECEIVED WITHIN THE SEVEN (7) DAY REVOCATION PERIOD.

    10.    Cooperation. During the Severance Period, Executive agrees to fully cooperate with the Company in all matters relating to the winding up of Executive’s work, including, but not limited to, the orderly transfer of any such pending work to such other employees as the Company designates. Furthermore, during and after the Severance Period, Executive further agrees to provide reasonable assistance in connection with any current or future investigations or litigation in which the Company is or becomes involved and of which Executive has relevant information.

11.    Miscellaneous.

    (a)    Should any portion, term or provision of this Agreement be declared or determined by any court to be illegal, invalid or unenforceable, the validity or the remaining portions, terms and provisions shall not be affected thereby, and the illegal, invalid or unenforceable portion, term or provision shall be deemed not to be part of this Agreement.

    (b)    The Parties agree that the failure of a Party at any time to require performance of any provision of this Agreement shall not affect, diminish, obviate or void in any way the Party’s full right or ability to require performance of the same or any other provision of this Agreement at any time thereafter.

    (c)    This Agreement shall inure to the benefit of and shall be binding upon Executive, Executive’sheirs, administrators, representatives, executors, successors and assigns and upon the successors and assigns of the Company.

    (d)    The headings of the paragraphs of this Agreement are for convenience only and are not binding on any interpretation of this Agreement. This Agreement may be executed in counterparts.

    (e)    Counterparts may be transmitted and/or signed by facsimile or electronic mail. The effectiveness of any such documents and signatures shall have the same force and effect as manually signed originals and shall be binding on the Parties to the same extent as a manually signed original thereof.

    (f)    This Agreement embodies the complete agreement and understanding between the Parties relating to the subject matter hereof and supersedes and preempts any contemporaneous or prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way; provided that the covenants contained in this Agreement are independent of, supplemental to, and do not modify, supersede or restrict (and shall not be modified, superseded or restricted by) any noncompetition, nonsolicitation, nondisparagement, confidentiality or other restrictive covenant in any other prior, current or future agreement (including, but not limited to, the Employment Agreement and the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement referenced in Section 6 of the Employment Agreement).

(g)    Notwithstanding anything to the contrary in this Agreement, the provisions of Sections 5 through 18 of the Employment Agreement survive the termination of Executive’s employment with the Company.

EXECUTIVE HEREBY ACKNOWLEDGES THAT HE HAS BEEN GIVEN A PERIOD OF AT LEAST TWENTY-ONE (21) DAYS TO CONSIDER WHETHER TO EXECUTE THIS AGREEMENT, AND THAT CHANGES TO THIS AGREEMENT, WHETHER MATERIAL OR IMMATERIAL,

3

WILL NOT RESTART THE RUNNING OF THE TWENTY-ONE (21) DAY PERIOD. EXECUTIVE ALSO ACKNOWLEDGES THAT HE WAS ADVISED BY THE COMPANY IN WRITING TO CONSULT WITH AN ATTORNEY BEFORE SIGNING THIS AGREEMENT.

IN WITNESS WHEREOF, the Parties have executed this Agreement, effective as of the execution by both Parties to this Agreement.

                    9 METERS BIOPHARMA, INC.

By:    /s/ Mark A. Sirgo

                    Name: Mark A. Sirgo

                    Title:    Chairman

                    DATE: 5/29/2023

EMPLOYEE:

/s/ John Temperato (SEAL)

                John Temperato

DATE: 5/28/2023

4

EX-99.1

Press Release

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (Nasdaq: NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.

Mark Sirgo, Chairman of the Board of 9 Meters, stated, “On behalf of the Board of Directors, I want to thank John for his service and dedication to the Company.” The Board of Directors has appointed Bethany Sensenig, Chief Financial Officer of 9 Meters, to serve as interim Chief Executive Officer in addition to her current responsibilities.

The Company previously announced plans to conduct a Phase 3 trial with vurolenatide in patients with short bowel syndrome (SBS). However, following further consideration of feedback received previously from the U.S. Food and Drug Administration (FDA) and input from thought leaders and investors, the Company now believes an additional Phase 2 trial may maximize the potential for vurolenatide. In addition, as the Company continues to assess various strategic alternatives, if and when funding is available, the Company will update on the initiation of the timing of this Phase 2 trial.

About 9 Meters Biopharma

9 Meters Biopharma, Inc. is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. 9 Meters is developing vurolenatide, a proprietary long-acting GLP-1 agonist for short bowel syndrome as well as an anti-GIP monoclonal antibody, NM-136, for obesity disorders.

For more information please visit or follow 9 Meters on Twitter,LinkedIn, and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements based upon 9 Meters' current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, anticipated milestones, and any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: reliance on key personnel and the risks business continuity of shifting the CEO role and responsibilities at this critical time; our review of strategic alternatives, and the results of such review; our need to raise additional capital to fund our operations for at least the next 12 months as a going concern and to advance our product candidates and preclinical programs, including in light of current stock market conditions; uncertainties regarding our continued listing on Nasdaq; risks

Press Release

related to our ability to successfully implement our business plans, including reliance on our lead product candidate; uncertainties associated with the clinical development and regulatory approval of product candidates, including any delays associated therewith; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; intellectual property risks; reliance on collaborators; reliance on research and development partners; and risks related to cybersecurity and data privacy. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in 9 Meters' Annual Report on Form 10-K for the year ended December 31, 2022, as amended and supplemented by our Quarterly Reports on Form 10-Q and in other filings that 9 Meters has made and future filings 9 Meters will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. 9 Meters expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Corporate and Media Contact

Al Medwar

SVP, Investor Relations & Corporate Communications

9 Meters Biopharma, Inc.

investor-relations@9meters.com

Source: 9 Meters Biopharma, Inc.

XML

Cover	May 26, 2023
Cover [Abstract]
Document Type	8-K
Document Period End Date	May 26, 2023
Entity Registrant Name	9 Meters Biopharma, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-37797
Entity Tax Identification Number	27-3948465
City Area Code	919
Local Phone Number	275-1933
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock $0.0001 Par Value
Trading Symbol	NMTR
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001551986
Amendment Flag	false
Entity Addresses [Line Items]
Entity Address, Address Line One	4509 Creedmoor Road
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Raleigh
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27612